Sequential [¹⁸F]FDG-[¹⁸F]FMISO PET and Multiparametric MRI at 3T for Insights into Breast Cancer Heterogeneity and Correlation with Patient Outcomes: First Clinical Experience

Table 2

Imaging data of all study cases.

ID	Volume	TIRM	T2w	ADC	DCEnative	DCEearly	DCEdelayed	IE	WO	FMISOmean	FMISOmax	FMISO TBRmean	FMISO TBRmax	FDGmean	FDGmax	FDG TBRmean	FDG TBRmax
1	35.5	379	348	1271	141	697	709	3.9	0.1	0.8	1.3	1	1.6	6.3	16.5	2.7	7.2
2	29.5	251	176	n/a	74	250	205	2.4	−0.6	1.4	3.7	0.9	2.5	7.4	24.1	3.7	12.1
3	15	164	273	1242	406	713	756	0.8	0.1	0.8	1.3	0.6	0.9	2.3	6.5	1.2	3.3
4	193.9	199	216	1208	525	813	951	0.5	0.3	1.8	4.3	1.1	2.7	5.1	16.9	2.1	7
5	16.3	229	n/a	1056	275	503	534	0.8	0.1	1.3	2.1	1	1.6	5.7	16.2	3.2	9
6	10	206	168	955	244	511	539	1.1	0.1	1.2	2	0.8	1.3	8.1	17.8	4.1	8.9
7	91	197	344	892	262	264	793	0	2	1.2	2.7	0.7	1.5	3.5	13.5	1.7	6.4
8	8.5	136	416	1182	329	340	435	0	0.3	0.5	0.9	0.4	0.7	1.1	3.2	0.5	1.3
9	12.5	171	176	1509	155	163	442	0.1	1.8	1	1.5	0.8	1.3	1.7	2.5	1	1.5
10	176	256	139	685	350	600	604	0.7	0	2	4.4	1.3	2.8	7.6	17.3	3.8	8.7

T2w, intensity on T2-weighted magnetic resonance imaging (MRI) (arb. unit); ADC, apparent diffusion coefficient (×10⁻⁶ mm²/s); TIRM, intensity on turbo inversion recovery magnitude MRI (arb. unit); DCE, intensity on dynamic contrast enhanced MRI (arb. unit); IE, initial enhancement ratio (arb. unit); WO, washout ratio (arb. unit); FMISO/FDG_mean, region of interest mean standard uptake value (SUV) of [¹⁸F]fluoromisonidazole or [¹⁸F]fluoro-deoxy-glucose (g/ml); FMISO/FDG_max, region of interest maximum SUV of FMISO or FDG (g/ml); TBR_mean/max, tumor to background ratio based on mean/max SUV in the tumor normalized to mean SUV in the aorta (arb. unit).